Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
Mallinckrodt
Merck
Farmers Insurance
Novartis
Cantor Fitzgerald
Express Scripts
QuintilesIMS
Queensland Health
Chinese Patent Office

Generated: January 22, 2018

DrugPatentWatch Database Preview

OXAYDO Drug Profile

« Back to Dashboard

When do Oxaydo patents expire, and what generic alternatives are available?

Oxaydo is a drug marketed by Egalet Us Inc and is included in one NDA. There are six patents protecting this drug.

This drug has thirteen patent family members in six countries.

The generic ingredient in OXAYDO is oxycodone hydrochloride. There are seventeen drug master file entries for this compound. Fifty-nine suppliers are listed for this compound. Additional details are available on the oxycodone hydrochloride profile page.
Summary for OXAYDO
International Patents:13
US Patents:6
Applicants:1
NDAs:1
Suppliers / Packagers: 3
Bulk Api Vendors: 35
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:OXAYDO at DailyMed
Drug patent expirations by year for OXAYDO
Pharmacology for OXAYDO
Drug ClassOpioid Agonist
Mechanism of ActionFull Opioid Agonists

US Patents and Regulatory Information for OXAYDO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Egalet Us Inc OXAYDO oxycodone hydrochloride TABLET;ORAL 202080-001 Jun 17, 2011 RX No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Egalet Us Inc OXAYDO oxycodone hydrochloride TABLET;ORAL 202080-002 Jun 17, 2011 RX No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Egalet Us Inc OXAYDO oxycodone hydrochloride TABLET;ORAL 202080-001 Jun 17, 2011 RX No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Egalet Us Inc OXAYDO oxycodone hydrochloride TABLET;ORAL 202080-002 Jun 17, 2011 RX No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Egalet Us Inc OXAYDO oxycodone hydrochloride TABLET;ORAL 202080-002 Jun 17, 2011 RX No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Egalet Us Inc OXAYDO oxycodone hydrochloride TABLET;ORAL 202080-001 Jun 17, 2011 RX No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Egalet Us Inc OXAYDO oxycodone hydrochloride TABLET;ORAL 202080-001 Jun 17, 2011 RX No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Egalet Us Inc OXAYDO oxycodone hydrochloride TABLET;ORAL 202080-001 Jun 17, 2011 RX No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Egalet Us Inc OXAYDO oxycodone hydrochloride TABLET;ORAL 202080-001 Jun 17, 2011 RX No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Egalet Us Inc OXAYDO oxycodone hydrochloride TABLET;ORAL 202080-002 Jun 17, 2011 RX No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for OXAYDO

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,476,402 Methods and compositions for deterring abuse of opioid containing dosage forms ➤ Subscribe
8,101,630 Extended release opioid abuse deterrent compositions and methods of making same ➤ Subscribe
8,822,489 Abuse deterrent compositions and methods of making same ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for OXAYDO

Supplementary Protection Certificates for OXAYDO

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
292 Luxembourg ➤ Subscribe PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Novartis
Deloitte
Merck
Johnson and Johnson
Fish and Richardson
Colorcon
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot